The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Randomised Control Trial Of Three Treatments For Adolescent Stutterers
Funder
National Health and Medical Research Council
Funding Amount
$376,320.00
Summary
Effective communication is an essential of everyday life, and stuttering impairs this function. Those who stutter may find effective communication impossible, and severe cases may be rendered almost mute. Clinically significant anxiety figures prominently in the disorder with almost half of those seeking treatment warranting a comorbid diagnosis of social phobia. The adolescent years are generally regarded as a difficult time of life, at which time the potential effects of disfigured speech can ....Effective communication is an essential of everyday life, and stuttering impairs this function. Those who stutter may find effective communication impossible, and severe cases may be rendered almost mute. Clinically significant anxiety figures prominently in the disorder with almost half of those seeking treatment warranting a comorbid diagnosis of social phobia. The adolescent years are generally regarded as a difficult time of life, at which time the potential effects of disfigured speech can be devastating. There has been much research and development of treatments for children and adults who stutter, proven effective treatments are available for those age groups. However, little is known about how to treat adolescents who stutter, and there has been little research and development to find the best treatment-s for this age group. The present proposal is for a randomised, controlled trial of three treatments that have been shown recently to have promise as treatment methods for this age group of patients. The trial will compare (1) a treatment that involves biofeedback muscle activity during speech, (2) a treatment that involves biofeedback of voice box activity during speech, and (3) a variant of a standard treatment that trains the speaker in a new speech pattern. The control group will receive no treatment. The trial extends for a period of 12 months after the subjects are randomly allocated to a treatment group or a control group. The subjects' speech will be assessed in a variety of situations in the clinic and during everyday life. The prime outcome measure will be percentage of syllables stuttered, and secondary measures will be the time required for treatment and how natural the patients sound after treatment. At the conclusion of the trial, the subjects in the control group will be given the treatment that was shown to be most effective.Read moreRead less
Randomised, Double-blind, Placebo Controlled Trial Of Lithium Carbonate For The Management Of Human Cannabis Withdrawal
Funder
National Health and Medical Research Council
Funding Amount
$523,509.00
Summary
This project aims to help dependent cannabis users stop using cannabis by exploring the safety and effectiveness of lithium in reducing the severity of withdrawal that occurs on cessation of use. Participants will be admitted to an inpatient drug treatment unit (Sydney or Lismore) for 7 days and will be randomly assigned to receive either lithium or placebo. Participants receiving lithium are expected to have less severe withdrawal and higher rates of abstinence from cannabis at follow-up.
Investigation Of Dysfunction Of SIGMAR1 In Transgenic Mouse Models, A Novel Gene Implicated In Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$492,119.00
Summary
At present, there are no effective therapies for frontotemporal dementia or motor neuron disease. We have identified the SIGMAR1 gene as having a crucial role for these diseases. More importantly, there are therapeutically relevant small molecule drugs that are known to modulate the activity of this gene. We aim to determine the efficacy of pharmacological modulation of Sigma-1 receptor activity in mouse models of dementia.
Many approaches to the prevention and treatment of allergy and associated asthma are dependent on the identification of the allergens producing the inflammation. This applies to new methods of determining the exposure to allergens and measuring the effectiveness of procedures which minimise allergen exposure. Diagnostic and immunotherapeutic measures require reliable preparations of allergens. The presence of important allergens in extracts however can be variable and often low so it important t ....Many approaches to the prevention and treatment of allergy and associated asthma are dependent on the identification of the allergens producing the inflammation. This applies to new methods of determining the exposure to allergens and measuring the effectiveness of procedures which minimise allergen exposure. Diagnostic and immunotherapeutic measures require reliable preparations of allergens. The presence of important allergens in extracts however can be variable and often low so it important that the allergens be identified and monitored. It is also important that new forms of immunotherapy being developed consider the responses to all allergens. Allergy to the cat is, behind house dust mite, the second most frequent allergy associated with asthma in most developed countries and brief exposure to a cat frequently induces life-threatening attacks. Almost all of the study of cat allergens have concentrated on a single allergen called Fel d 1. Although it importance is undisputed critical reading of the literature show it is only responsible for 50% of the IgE binding in cat extracts and recent work on cross allergy to cat and dogs and experimental therapy based on Fel d 1 point to the importance of other allergens. Experience with other source of allergens has shown that at least several allergens are usually important. It is also apparent from other studies that some allergens which are difficult to detect in extracts, and cannot be readily studied by immunochemistry are important. This project will use both cDNA cloning and immunochemistry to identify and characterize the other cat allergens and determine there relative importance. In particular it intended that they can be used, along with Fel d 1, to develop new types of immunotherapy.Read moreRead less
This Australian-led, investigator initiated and conducted study, is the first and only large scale clinical trial designed to assess the balance of potential benefits and risks of early rapid blood pressure lowering in intracerebral haemorrhage stroke, a disease in which there is still no convincing evidence of benefit from any medical treatment, where the role of surgery remains controversial, and from which the chances of surviving has failed to improve in recent decades.
Developing A Skin Test For Early Diagnosis Of Alzheimer's Disease And For Monitoring Effectiveness Of Treatment
Funder
National Health and Medical Research Council
Funding Amount
$285,000.00
Summary
Approximately 140,000 Australians suffer from Alzheimer's disease (AD). As the ageing population continues to grow, this number will double by the middle of the next century unless a cure or prevention is found. Scientists are continuously seeking new, more effective diagnostic tests in an effort to make it easier to diagnose AD in its early stages. Being able to recognize symptoms early and obtain an accurate diagnosis would give affected individuals a greater chance of benefiting from putative ....Approximately 140,000 Australians suffer from Alzheimer's disease (AD). As the ageing population continues to grow, this number will double by the middle of the next century unless a cure or prevention is found. Scientists are continuously seeking new, more effective diagnostic tests in an effort to make it easier to diagnose AD in its early stages. Being able to recognize symptoms early and obtain an accurate diagnosis would give affected individuals a greater chance of benefiting from putative treatments. However, there is no single, comprehensive diagnostic test for AD. Diagnostic tests (including peripheral markers) that can help to reliably diagnose AD at an early stage are needed as are tests that can help in monitoring the progression of AD, including response to therapy. The accuracy and clinical utility of previously proposed peripheral markers (platelets and pupil dilation test) is questionable. The only way to confirm a diagnosis of AD is through autopsy. We have obtained a provisional patent application for the use of a skin test for early diagnosis of AD (Patent No: PQ2881-99). This test is based on our extensive research over the past decade to understand the biochemical mechanisms underlying the txic vascular actions of beta amyloid protein. This protein has been implicated in the pathology of AD and it accumulates in the brain, peripheral tissues and is present in circulating blood of AD patients. The test is based on our discovery that vascular effects of Ab could be detected in the peripheral microcirculation .We now wish to further examine the utility of this novel skin test. If the test is sensitive, it could be used for screening; if it is specific it would be useful for confirmation of suspected AD. If the test is sensitive to change in clinical status it would help select treatments that might cure or improve the symptoms of AD.Read moreRead less